This randomized phase II trial studies hyperthermic intraperitoneal chemotherapy or intraperitoneal chemotherapy in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer. In hyperthermic intraperitoneal chemotherapy, the chemotherapy is warmed before being used and may help the drugs get into the cancer cells better, minimize the toxicity of the drugs on normal cells, and help to kill any cancer cells left over after surgery. Intraperitoneal chemotherapy is delivered directly to the abdominal cavity to help treat cancer. It is not yet known whether hyperthermic intraperitoneal chemotherapy or intraperitoneal chemotherapy works better in improving quality of life in patients with ovarian, fallopian tube, or primary peritoneal cancer.